Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash & Equivalents (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Cash & Equivalents for 7 consecutive years, with $352.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 46.17% to $352.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $352.3 million, a 46.17% increase, with the full-year FY2025 number at $352.3 million, up 46.17% from a year prior.
  • Cash & Equivalents was $352.3 million for Q4 2025 at Fulcrum Therapeutics, up from $47.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $352.3 million in Q4 2025 to a low of $25.6 million in Q4 2023.
  • A 5-year average of $86.8 million and a median of $47.1 million in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 66.93% in 2022, then soared 842.85% in 2024.
  • Fulcrum Therapeutics' Cash & Equivalents stood at $35.4 million in 2021, then decreased by 0.89% to $35.1 million in 2022, then decreased by 27.17% to $25.6 million in 2023, then skyrocketed by 842.85% to $241.0 million in 2024, then soared by 46.17% to $352.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Cash & Equivalents are $352.3 million (Q4 2025), $47.1 million (Q3 2025), and $226.6 million (Q1 2025).